產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白與其它公司提供的重組蛋白不同，rHuMIP-3α/CCL20蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白
| Synonyms | LARC, Beta-chemokine Exodus-1, Liver and Activation-regulated Chemokine |
| Species | Human |
| Accession | P78556 |
| GeneID | 6364 |
| Source | 重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白Escherichia coli. |
| Molecular Weight | Approximately 8.0 kDa, a single non-glycosylated polypeptide chain containing 70 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | ASNFDCCLGY TDRILHPKFI VGFTRQLANE GCDINAIIFH TKKKLSVCAN PKQTWVKYIV RLLSKKVKNM |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 10-50 ng/ml. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 100 mM NaCl. |
| Endotoxin | Less than 1 EU/μg of rHuMIP-3α/CCL20 as determined by LAL method. |
| Reconstitution | 重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人類(lèi)巨噬細(xì)胞炎性蛋白質(zhì)3α/ CCL20蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Chavan R, Marfatia KA, An IC, et al. 2006. J Virol, 80: 7676-87. 2. Hosokawa Y, Hosokawa I, Ozaki K, et al. 2005. Clin Exp Immunol, 142: 285-91. 3. Hirota K, Yoshitomi H, Hashimoto M, et al. 2007. J Exp Med, 204: 2803-12. 4. Francis JN, Sabroe I, Lloyd CM, et al. 2008. Clin Exp Immunol, 152: 440-7. |
| Background | CCL20, also named LARC (Liver and Activation-regulated Chemokine), is encoded by CCL20 located on chromosome 2 in humans. The expression can be induced by LPS and some inflammatory cytokines, and it is at a high level in lymph nodes, PBL, fatal liver, fatal lung, appendix and so on. CCL20 has functions of chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. CCL20 elicits it effects by binding with CCR6 receptor. |
